Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s…
- Establishes co-development and co-commercialization agreement on Foghorn’s selective BRM program and an additional undisclosed program - Collaboration includes three additional discovery programs - Foghorn to receive $300 million…